Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL20578365 | 0.89 | ADORA2A (0.49) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL1367259 | 0.81 | AXL (0.52) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL19661007 | 0.79 | ADORA2A (0.46) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL5334843 | 0.79 | ADORA2A (0.50) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL30277827 | 0.79 | ADORA2A (0.50) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL24170311 | 0.79 | ADORA2A (0.50) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL20783852 | 0.79 | RAB9A (0.41) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL61922 | 0.79 | ADORA2A (0.53) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30277817 | 0.78 | ADORA2A (0.49) | ADORA2AADORA1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL24995357 | 0.76 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2BELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-3421465-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022002118-A1 | FUSED-RING HETEROCYCLE DERIVATIVE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2022-01-06 | — | — | WO | disclosed |
| EP-3932404-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-01-05 | — | — | EP | disclosed |
| EP-3421464-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2021-11-24 | — | — | EP | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
| EP-3647311-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1956009-A1 | AROMATIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007056214-A2 | N-ALKYL-N-ARYL-THIENOPYRIMIDIN-R-AMINES AND USES THEREOF | CYTOVIA, INC (US) | 2007-05-18 | — | — | WO | disclosed |
| US-RE39267-E1 | Thienopyrimidine-based inhibitors of the SRC family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-09-05 | — | — | US | disclosed |
| US-6503914-B1 | Thienopyrimidine-based inhibitors of the Src family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | ADORA2A 1605/4885ADORA1 585/4885POLB 3362/4885 |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | ADORA2A 2291/4885ADORA1 3157/4885POLB 1679/4885 |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | KHK, KHDRBS1, KHSRP | ADORA2A 4466/4885ADORA1 4412/4885POLB 4381/4885 |
| US-20090182142-A1 | Aromatic Compound | HRH4, CCR4, HRH3 | ADORA2A 2487/4885ADORA1 769/4885POLB 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.